DeepQure Completes Last Patient Treatment in MDFS FIH Clinical Trial for HyperQure™

DeepQure, a leader in innovative medical devices, announced today the successful completion of the final surgery in its domestic exploratory clinical trial for HyperQure™, a next-generation treatment for hypertension.

The 10th and final patient was treated using HyperQure™, a laparoscopic-based Extravascular Renal Denervation (RDN) device. Since the first patient enrollment in February 2024, the trial has focused on 10 patients with resistant hypertension whose blood pressure remained uncontrolled despite taking three or more medications.

This completion marks a pivotal milestone toward the commercialization of HyperQure™. Preliminary observations from the trial indicate statistically significant blood pressure reduction and stable patient outcomes. While the final data is moving into the data lock phase, internal assessments describe the results as "highly encouraging."

DeepQure plans to finalize the clinical results following one year of post-operative monitoring and data analysis. Starting in 2026, the company will present interim results at major global conferences in urology and cardiology to demonstrate HyperQure™'s technical superiority to the international medical community.

Unlike traditional intravascular catheters, HyperQure™ utilizes a laparoscopic approach to wrap and denervate the sympathetic nerves from the outside of the renal artery. This world-first extravascular technology ensures complete nerve ablation without damaging the arterial walls, offering superior therapeutic efficacy compared to existing methods.

Global Momentum in the U.S. DeepQure is also accelerating its entry into the U.S. market. Following the U.S. clinical launch in January 2025, multi-center IDE clinical trials are currently underway at five prestigious institutions:

• UC Irvine

• Stanford University

• Mayo Clinic

• University of Florida

• Henry Ford Health System

"With the successful completion of the Korean clinical treatment, we expect our global trials to gain further momentum," said a DeepQure representative. "We are committed to providing a life-changing solution that nears a 'cure' for patients suffering from resistant hypertension."

Source